ibrutinib resistance: is it predictable? what to do?
Published 6 years ago • 626 plays • Length 23:08Download video MP4
Download video MP3
Similar videos
-
29:14
ibrutinib resistance-mechanisms and options in cll
-
25:09
cll: long-term updates on ibrutinib and idelalisib
-
27:37
therapeutic options for richter’s syndrome
-
3:28
case 4: resistance to ibrutinib in cll
-
1:42
deciphering ibrutinib resistance in chronic lymphocytic leukemia
-
25:17
what to do after btki therapy fails
-
14:48
debate: best frontline regimen for a cll patient aged 60 who requires therapy - ibrutinib
-
6:30
cll whiteboard #1: introduction & mechanisms of action of bcr signaling inhibitors
-
11:59
assessment of successful thrombolysis in stemi : dr. akif baig
-
1:44
flowsaver blood return system
-
4:35
immunity: stripline method
-
12:34
debate: is it appropriate to treat patients with cll earlier in the era of novel agents? - no
-
2:37
resistance to acalabrutinib in cll is mediated by btk mutations
-
23:41
expert perspectives: chronic lymphocytic leukemia (cll)
-
20:48
cll: btk inhibitors vs chemoimmunotherapy as initial treatment
-
1:27
managing cardiotoxicity associated with the use of ibrutinib
-
5:52
understanding ultra high-risk cll and advances with ibrutinib therapy
-
49:01
chronic lymphocytic leukemia: case discussions
-
2:33
btki resistance and it's management
-
20:23
cll: update on approved tkis and their use in clinical practice
-
26:55
new insights into the biology and treatment of waldenström macroglobulinemia
-
4:43
phase ib trial of ianalumab plus ibrutinib for cll